












Procedure file

Basic information		
DEC - Discharge procedure	2023/2179(DEC)	Procedure completed, awaiting publication in Official Journal
2022 discharge: Innovative Health Initiative Joint Undertaking (IHI JU)		
Subject 8.70.03.12 2022 discharge		

Key players			
European Parliament	Committee responsible	Rapporteur	Appointed
	 Budgetary Control	 WIEZIK Michal	14/06/2023
		Shadow rapporteur	
		 WINZIG Angelika	
		 CREU Corina	
		 THIOLLET François	
		 ADINOLFI Matteo	
		 CZARNECKI Ryszard	
		 OMARJEE Younous	
	Committee for opinion	Rapporteur for opinion	Appointed
	 Environment, Public Health and Food Safety	The committee decided not to give an opinion.	
	 Industry, Research and Energy	The committee decided not to give an opinion.	
European Commission	Commission DG Budget	Commissioner HAHN Johannes	

Key events			
28/06/2023	Non-legislative basic document published	COM(2023)0391	
12/09/2023	Committee referral announced in Parliament		
22/02/2024	Vote in committee		

12/03/2024	Committee report tabled for plenary	A9-0093/2024	
10/04/2024	Debate in Parliament		
11/04/2024	Decision by Parliament		

Technical information

Procedure reference	2023/2179(DEC)
Procedure type	DEC - Discharge procedure
Stage reached in procedure	Procedure completed, awaiting publication in Official Journal
Committee dossier	CONT/9/13020

Documentation gateway

Non-legislative basic document	COM(2023)0391	28/06/2023	EC	
Court of Auditors: opinion, report	N9-0085/2023 OJ C 000 16.11.2023, p. 0000	14/11/2023	CofA	
Committee draft report	PE753.499	15/12/2023	EP	
Amendments tabled in committee	PE757.345	31/01/2024	EP	
Supplementary non-legislative basic document	06182/2024	12/03/2024	CSL	
Committee report tabled for plenary, single reading	A9-0093/2024	12/03/2024	EP	
Text adopted by Parliament, single reading	T9-0274/2024	11/04/2024	EP	Summary

2022 discharge: Innovative Health Initiative Joint Undertaking (IHI JU)

The European Parliament decided to grant discharge to the Executive Director of the Innovative Health Initiative Joint Undertaking (IHI) in respect of the implementation of its budget for the financial year 2022 and approve the closure of the Joint Undertakings accounts.

Noting that the Court of Auditors found that the annual accounts of the Joint Undertaking for the financial year 2022 present fairly the financial situation of the Joint Undertaking on 31 December 2022, as well as the results of its operations, Parliament adopted, by 535 votes to 49 with 10 abstentions, a resolution containing a series of observations which form an integral part of the discharge decision.

Budgetary and financial management

The IHI JU available budget for 2022 was EUR 272.4 million in commitment appropriations (EUR 11 million in 2021) and EUR 174.8 million in payment appropriations (EUR 210.4 million in 2021). The budget execution of the commitment appropriations and the payment appropriations reached 96.60 % (75.91 % in 2021) and 86.25 % (95.39 % in 2021) respectively.

At the end of 2022, the IHI JU had fully committed the maximum Union operational contributions of EUR 966 million for signed grant agreements under the programme; notes, ten years after the end of the FP7 programme, around EUR 44.9 million (or 5 %) still remains to be paid for projects yet to be completed. This gap corresponds to 5 projects carrying out research on antimicrobial resistance (AMR).

Private members had legally committed to provide in-kind contributions of EUR 914.2 million or 94.6 % of the minimum operational target of EUR 966 million and that, of that committed amount, they reported EUR 831.9 million (or 86 % of the target) at the end of 2022.

Members noted that the IHI JU has performed well against the majority of the IMI2 key performance indicators (KPIs), often exceeding the established targets. They welcomed, in particular, the fact that the IHI JUs projects funded under IMI2 have completed 24 regulatory procedures.

Moreover, Parliament noted with satisfaction that a share of 58.3 % (above the 50 % target) of the IHI JUs projects funded under IMI2 have made their resources and outputs accessible beyond the consortia partners. Members highlighted examples such as the library of chemical compounds, the European Compound Collection, established by the ESCulab project, the open source RADAR-base data platform developed by RADAR-CNS, the European federated data network, established by the EHDEN project, or the self-sustaining pluripotent stem cells biobank delivered by EBiSC2.

Other observations

The resolution also contains a series of observations on management and control systems, procurement and staff policy.

In particular, it noted the following:

- the majority of IHI JUs contractual commitments in 2022 were concluded on the basis of existing multiannual framework contracts;
- all procedures were administered in compliance with the IHI JU Financial Rules and the Financial Regulation to ensure fair competition amongst economic operators, and the most sound and efficient use of IHI JU funds;
- the staff establishment plan allows for 39 temporary agents, 15 contract agents and 1 seconded national expert, in total 55 members of staff; notes that, on 31 December 2022, there were 49 positions occupied;
- as regards gender balance and geographical balance, that around 65 % of staff are women and around 35 % are male, coming from 15 different nationalities;
- the Joint Undertaking reported a representative error rate of 2.1% and a residual error rate of 0.8% for its FP7 expenditure and a representative error rate of 2.7% and a residual error rate of 0.9% for its Horizon 2020 expenditure;
- the Court found no errors or control weaknesses at the level of the Joint Undertaking's beneficiaries;
- the Joint Undertaking developed and implemented a comprehensive risk-based approach to ex-ante controls taking into account the specific risk circumstances of the IHI Joint Undertaking;
- the Joint Undertaking developed a risk-based ex-post audit approach with the aim of reducing its error rate through a more targeted sample to detect beneficiaries most at risk of error. The Court concluded that Joint Undertakings with a well-developed risk-based ex-post audit approach have a lower residual error rate than the average Joint Undertaking without such an approach, due to the systematic identification and audit of the beneficiaries most at risk.